Dana dhuwit saben saham RedHill Biopharma Ltd (RDHL)

Lambang korporat lan logo RedHill Biopharma Ltd (RDHL)

RedHill Biopharma generates revenue from the sale of gastrointestinal therapies, betting on the drug Talicia and oncology research. Partnerships with global distributors help the company scale distribution and advance joint development projects. The cash per share allows for a real-time assessment of the issuer's solvency, where the value 0.58 represents the current metric. The commercial growth stage and the expansion of indications for existing drugs will serve as key revenue drivers.

RedHill Biopharma (RDHL) - Dhuwit awis saben saham saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan RedHill Biopharma

- rincian posisi dhuwit lan arus kas:
Analisis komprehensif perusahaan:RedHill Biopharma Ltd. (RDHL)
Produk asil prodhuksi RedHill Biopharma Ltd.

RedHill Biopharma's independence from macro cycles requires significant reserves to fund clinical trials and drug commercialization. This indicator measures the volume of liquid assets per common share. An increase in this metric confirms strengthening financial stability and a reduction in debt risks. It is critical for investors to maintain a balance between capital security and capital efficiency. By analyzing the cash position per share, one can assess the issuer's real margin of safety.